Training Matrix for ATMP Manufacturing Personnel in 2023: GMP + Aseptic + Viral Vector Skills Training Matrix for ATMP Manufacturing Personnel in 2023: GMP + Aseptic + Viral Vector Skills Advanced therapy medicinal products (ATMPs) are at the forefront of innovation in healthcare, but their manufacturing processes are complex and strictly regulated. This article serves as a step-by-step tutorial on developing a comprehensive training matrix for ATMP manufacturing personnel, focusing on Good Manufacturing Practice (GMP), aseptic processing, and viral vector skills. The goal is to ensure compliance with the stringent requirements set forth by regulatory bodies such as the FDA,…

EU ATMP Regulatory Strategy in 2023 – Playbook 7 EU ATMP Regulatory Strategy in 2023 – Playbook 7 Advanced Therapy Medicinal Products (ATMPs) represent a cutting-edge and dynamic area of pharmaceutical development, enhancing therapeutic options for various diseases. With the European Medicines Agency’s Committee for Advanced Therapies (EMA CAT) framework evolving, it is imperative for regulatory affairs, clinical development, and quality assurance professionals engaged in ATMP regulatory consulting to have a robust understanding of the process involved. This article focuses on providing a comprehensive step-by-step guide to navigating the EU ATMP regulatory landscape. Step 1: Understanding the Definition and Classification…

Process Validation Approach for Personalized ATMPs in 2023: How to Defend to Inspectors Process Validation Approach for Personalized ATMPs in 2023: How to Defend to Inspectors The development and manufacturing of Advanced Therapy Medicinal Products (ATMPs) is a complex process, especially given the unique challenges they pose. This article provides a detailed step-by-step tutorial aimed at Regulatory Affairs, CMC, Clinical Development, and QA teams involved in the production of personalized ATMPs. The focus is on establishing a robust process validation approach, ensuring compliance with regulatory agencies, and effectively defending your validation strategies during inspections. Step 1: Understanding the Regulatory Framework…

EU ATMP Regulatory Strategy in – Playbook 6 EU ATMP Regulatory Strategy in – Playbook 6 The regulatory landscape for Advanced Therapy Medicinal Products (ATMPs) within the European Union (EU) continues to evolve, influenced by innovations in biotechnology and the need for robust, flexible frameworks capable of accommodating these advancements. For companies and professionals involved in ATMP regulatory consulting, understanding and navigating the procedures is essential for successful submissions and compliance. This article serves as a step-by-step tutorial guide, providing a detailed overview of the regulatory strategy for ATMPs under EU’s EMA framework, particularly focusing on the European Medicines Agency’s…

Supplier Qualification for Critical Starting Materials (CSMs) in 2023: Audit Checklist for ATMPs Supplier Qualification for Critical Starting Materials (CSMs) in 2023: Audit Checklist for ATMPs Step 1: Understanding the Regulatory Framework for CSMs in ATMP Manufacturing In the development and commercialization of Advanced Therapy Medicinal Products (ATMPs), one of the critical components is the selection and qualification of Critical Starting Materials (CSMs). Regulatory authorities such as the FDA and EMA have specified guidelines to ensure that CSMs meet the required quality standards, which are vital for the safe and effective production of ATMPs. Having a strong grasp of the…

EU ATMP Regulatory Strategy in – Playbook 5 EU ATMP Regulatory Strategy in – Playbook 5 The development of Advanced Therapy Medicinal Products (ATMPs) presents a unique set of challenges for regulatory affairs professionals. This comprehensive guide outlines the necessary steps to navigate the EU regulatory landscape, particularly under the EMA’s Committee for Advanced Therapies (CAT). The article focuses on practical actions, documentation requirements, and compliance considerations essential for a successful ATMP submission. Step 1: Understanding ATMP Classification and Types The first crucial step in any ATMP regulatory strategy is to understand the classification of the product. ATMPs can be…

Contamination Control Strategy for ATMP Cleanrooms in 2023: EU Annex 1/2 Alignment Contamination Control Strategy for ATMP Cleanrooms in 2023: EU Annex 1/2 Alignment Step 1: Understanding Regulatory Requirements for ATMP Cleanrooms The manufacturing of Advanced Therapy Medicinal Products (ATMPs) involves stringent regulatory requirements, particularly regarding cleanroom environments. In the United States, the FDA mandates adherence to Good Manufacturing Practices (GMP) as set forth in 21 CFR Parts 210 and 211, alongside recommendations from ICH Q7 concerning APIs. Moreover, the European Union’s new Annex 1 and Annex 2 provide specifications for sterile medicinal products, impacting ATMPs significantly. Annex 1 emphasizes…

EU ATMP Regulatory Strategy in – Playbook 4 EU ATMP Regulatory Strategy in – Playbook 4 Step 1: Understanding the Regulatory Framework for ATMPs In the realm of Advanced Therapy Medicinal Products (ATMPs), understanding the regulatory framework is crucial for successful development and commercialization. ATMPs encompass gene therapies, somatic cell therapies, and tissue-engineered products. The European Medicines Agency (EMA) and its Committee for Advanced Therapies (CAT) provide comprehensive guidance on the regulatory pathways for ATMPs. The primary legislation governing ATMPs is Regulation (EC) No 1394/2007, which lays out the definitions and requirements for marketing authorization. Familiarizing yourself with this regulation…

Qualified Person (QP) Strategy for EU ATMP Batch Certification in 2023: Governance Model Qualified Person (QP) Strategy for EU ATMP Batch Certification in 2023: Governance Model This comprehensive tutorial guides Regulatory Affairs, CMC, Clinical Development, QA, and ATMP/Cell & Gene Therapy Teams through the Qualified Person (QP) Strategy for EU ATMP Batch Certification. It focuses on effective governance implementations in alignment with regulatory compliance, particularly within the framework of EMA ATMP regulatory consulting. Step 1: Understanding the QP Role in ATMP Compliance In the regulatory framework governing Advanced Therapy Medicinal Products (ATMPs), the Qualified Person (QP) holds a pivotal role….

EU ATMP Regulatory Strategy in 2024 – Playbook 3 EU ATMP Regulatory Strategy in 2024 – Playbook 3 In an evolving landscape for Advanced Therapy Medicinal Products (ATMPs), understanding the regulatory pathways, documentation requirements, and compliance measures is critical for stakeholders in the pharmaceutical and clinical research industries. This guide serves as a detailed resource for US-based professionals engaged in ATMP regulatory consulting, outlining the necessary steps for compliance with European Medicines Agency (EMA) mandates and guidance under the Committee for Advanced Therapies (CAT). This document focally addresses centralized procedures, hospital exemptions, and key regulatory strategies pertaining to ATMPs. Step…